Showing 1 to 2 of 2 results


CSL Stock Plunges 15%, Exceeding Qantas's Market Value
CSL, an Australian biopharmaceutical giant, saw its market value plummet by 15 percent on Tuesday, exceeding Qantas's total value, due to US trade tensions, internal restructuring, and declining vaccination rates in the US.
CSL Stock Plunges 15%, Exceeding Qantas's Market Value
CSL, an Australian biopharmaceutical giant, saw its market value plummet by 15 percent on Tuesday, exceeding Qantas's total value, due to US trade tensions, internal restructuring, and declining vaccination rates in the US.
Progress
40% Bias Score

CSL Profits Rise Despite Flu Vaccine Revenue Drop Amid US Vaccine Hesitancy
CSL reported a 7 percent increase in net profit to $US2.01 billion, but its flu vaccine unit, Seqirus, experienced a 9 percent revenue drop due to lower US vaccination rates in the 18-64 age group, amid rising vaccine skepticism and Robert F Kennedy Jr.'s potential appointment as US Health Secretary...

CSL Profits Rise Despite Flu Vaccine Revenue Drop Amid US Vaccine Hesitancy
CSL reported a 7 percent increase in net profit to $US2.01 billion, but its flu vaccine unit, Seqirus, experienced a 9 percent revenue drop due to lower US vaccination rates in the 18-64 age group, amid rising vaccine skepticism and Robert F Kennedy Jr.'s potential appointment as US Health Secretary...
Progress
40% Bias Score
Showing 1 to 2 of 2 results